SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Rexahn Pharmaceuticals - RNN -- Ignore unavailable to you. Want to Upgrade?

To: caly who wrote (3)4/14/2010 6:08:18 PM
From: tuck  Respond to of 5
 
So in their first PR they try to ignore that they whiffed on the primary endpoint until they did a subset analysis of 14 patients. Prespecified or did they go fishing?

They have a first in class AKT inhibitor? Really? Keryx has had perifosine well into P2 for a while, and is going into p3 now.

Caveat emptor.

Cheers, Tuck



To: caly who wrote (3)4/19/2010 10:14:49 AM
From: caly2 Recommendations  Respond to of 5
 
Rexahn: Holes Galore in Serdaxin Data

thestreet.com

Interesting comments follow the article.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News